{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.97","value":"0.7"},{"groupId":"OG001","spread":"1.03","value":"-1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"CORE Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.97","value":"-0.7"},{"groupId":"OG001","spread":"1.12","value":"-1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"title":"CORE Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"description":"Standardized IGF-1 = IGF-1 value / ULN, where ULN is the upper limit of the normal range","dispersionType":"Standard Deviation","groups":[{"description":"Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days","id":"OG000","title":"Pasireotide LAR 40 mg"},{"description":"Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days","id":"OG001","title":"Pasireotide LAR 60 mg"}],"paramType":"MEAN","populationDescription":"Available data for analysis varies from visit to visit","reportingStatus":"POSTED","timeFrame":"CORE baseline up to approximately 24 weeks","title":"Change From Baseline in Standardized IGF-1 Values for Patients Treated With Pasireotide LAR Alone or With Concomitant Medications Used to Treat Acromegaly for CORE Visits (Extension Full Analysis Set)","type":"SECONDARY","unitOfMeasure":"mcg/L"}